ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant
reductions in LDL-cholesterol.
Investigated for use/treatment in diabetes mellitus type 2.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.